<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2023 Workiva--><!--r:b4b573b7-9bfc-4ba1-b8b5-dcea2a2e0e07,g:70deb569-374b-4fa5-84b1-b80d6dd040c6,d:d760589d10a142ec850423f46d4d1060--><html xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/1999/xhtml" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>kprx-20230207</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="ic17d4fc9834d42c89f5760ffacbfc11f_D20230207-20230207" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmQ3NjA1ODlkMTBhMTQyZWM4NTA0MjNmNDZkNGQxMDYwL3NlYzpkNzYwNTg5ZDEwYTE0MmVjODUwNDIzZjQ2ZDRkMTA2MF80L2ZyYWc6MWY3ODIwNWJlNjEwNDYzZGJiZGQyM2FkMTMxYmUwMDgvdGFibGU6OWZiZTkyYmJjYTA0NDVkOWJiMGE0YjYzZTlmYmRhMTMvdGFibGVyYW5nZTo5ZmJlOTJiYmNhMDQ0NWQ5YmIwYTRiNjNlOWZiZGExM18yLTEtMS0xLTMzOTc_abaa7a83-3927-49e9-944b-d09c80e3a4a5">0001372514</ix:nonNumeric><ix:nonNumeric contextRef="ic17d4fc9834d42c89f5760ffacbfc11f_D20230207-20230207" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOmQ3NjA1ODlkMTBhMTQyZWM4NTA0MjNmNDZkNGQxMDYwL3NlYzpkNzYwNTg5ZDEwYTE0MmVjODUwNDIzZjQ2ZDRkMTA2MF80L2ZyYWc6MWY3ODIwNWJlNjEwNDYzZGJiZGQyM2FkMTMxYmUwMDgvdGFibGU6OWZiZTkyYmJjYTA0NDVkOWJiMGE0YjYzZTlmYmRhMTMvdGFibGVyYW5nZTo5ZmJlOTJiYmNhMDQ0NWQ5YmIwYTRiNjNlOWZiZGExM18zLTEtMS0xLTMzOTc_df6e9172-e581-44f6-8942-ce8345357caf">false</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="kprx-20230207.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="ic17d4fc9834d42c89f5760ffacbfc11f_D20230207-20230207"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-07</xbrli:startDate><xbrli:endDate>2023-02-07</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="id760589d10a142ec850423f46d4d1060_1"></div><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:8pt;text-align:center"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">WASHINGTON, DC 20549</span></div><div style="margin-top:8pt;text-align:center"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="ic17d4fc9834d42c89f5760ffacbfc11f_D20230207-20230207" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmQ3NjA1ODlkMTBhMTQyZWM4NTA0MjNmNDZkNGQxMDYwL3NlYzpkNzYwNTg5ZDEwYTE0MmVjODUwNDIzZjQ2ZDRkMTA2MF8xL2ZyYWc6YTRlMzNmNjk2ZTdkNDYwNmE0OTVkYmQzZjA0MWZlZTkvdGV4dHJlZ2lvbjphNGUzM2Y2OTZlN2Q0NjA2YTQ5NWRiZDNmMDQxZmVlOV8xMzE4_3a685335-1f15-415f-85e3-b032823c53d2">8-K</ix:nonNumeric></span></div><div style="margin-top:8pt;text-align:center"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CURRENT REPORT PURSUANT</span></div><div style="text-align:center"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TO SECTION 13 OR 15(d) OF THE</span></div><div style="text-align:center"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECURITIES EXCHANGE ACT OF 1934</span></div><div style="margin-top:8pt;text-align:center"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date of report (Date of earliest event reported): </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ic17d4fc9834d42c89f5760ffacbfc11f_D20230207-20230207" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOmQ3NjA1ODlkMTBhMTQyZWM4NTA0MjNmNDZkNGQxMDYwL3NlYzpkNzYwNTg5ZDEwYTE0MmVjODUwNDIzZjQ2ZDRkMTA2MF8xL2ZyYWc6YTRlMzNmNjk2ZTdkNDYwNmE0OTVkYmQzZjA0MWZlZTkvdGV4dHJlZ2lvbjphNGUzM2Y2OTZlN2Q0NjA2YTQ5NWRiZDNmMDQxZmVlOV8yMjI_f171e282-8611-4a80-a30c-a67027229d86">February 7, 2023</ix:nonNumeric></span></div><div style="margin-top:8pt;text-align:center"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ic17d4fc9834d42c89f5760ffacbfc11f_D20230207-20230207" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmQ3NjA1ODlkMTBhMTQyZWM4NTA0MjNmNDZkNGQxMDYwL3NlYzpkNzYwNTg5ZDEwYTE0MmVjODUwNDIzZjQ2ZDRkMTA2MF8xL2ZyYWc6YTRlMzNmNjk2ZTdkNDYwNmE0OTVkYmQzZjA0MWZlZTkvdGV4dHJlZ2lvbjphNGUzM2Y2OTZlN2Q0NjA2YTQ5NWRiZDNmMDQxZmVlOV8xMzE0_c83bd2e4-3fb5-4733-8b15-2d123ea12acb">KIORA PHARMACEUTICALS, INC.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-top:8pt;text-align:center"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ic17d4fc9834d42c89f5760ffacbfc11f_D20230207-20230207" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmQ3NjA1ODlkMTBhMTQyZWM4NTA0MjNmNDZkNGQxMDYwL3NlYzpkNzYwNTg5ZDEwYTE0MmVjODUwNDIzZjQ2ZDRkMTA2MF8xL2ZyYWc6YTRlMzNmNjk2ZTdkNDYwNmE0OTVkYmQzZjA0MWZlZTkvdGV4dHJlZ2lvbjphNGUzM2Y2OTZlN2Q0NjA2YTQ5NWRiZDNmMDQxZmVlOV8xMzA4_265ca302-56bb-4336-bafe-839e3660b69d">Delaware</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(State or other jurisdiction of incorporation)</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.393%"><tr><td style="width:1.0%"></td><td style="width:42.967%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:54.833%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ic17d4fc9834d42c89f5760ffacbfc11f_D20230207-20230207" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmQ3NjA1ODlkMTBhMTQyZWM4NTA0MjNmNDZkNGQxMDYwL3NlYzpkNzYwNTg5ZDEwYTE0MmVjODUwNDIzZjQ2ZDRkMTA2MF8xL2ZyYWc6YTRlMzNmNjk2ZTdkNDYwNmE0OTVkYmQzZjA0MWZlZTkvdGFibGU6MDM4MzA3NmZkZTYyNGJkZThiODI1NTFhOTg3OThiYmEvdGFibGVyYW5nZTowMzgzMDc2ZmRlNjI0YmRlOGI4MjU1MWE5ODc5OGJiYV8wLTAtMS0xLTMzOTc_951fc2f3-99d3-4ca0-933e-8106e3eea999">001-36672</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ic17d4fc9834d42c89f5760ffacbfc11f_D20230207-20230207" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmQ3NjA1ODlkMTBhMTQyZWM4NTA0MjNmNDZkNGQxMDYwL3NlYzpkNzYwNTg5ZDEwYTE0MmVjODUwNDIzZjQ2ZDRkMTA2MF8xL2ZyYWc6YTRlMzNmNjk2ZTdkNDYwNmE0OTVkYmQzZjA0MWZlZTkvdGFibGU6MDM4MzA3NmZkZTYyNGJkZThiODI1NTFhOTg3OThiYmEvdGFibGVyYW5nZTowMzgzMDc2ZmRlNjI0YmRlOGI4MjU1MWE5ODc5OGJiYV8wLTEtMS0xLTMzOTc_7efd7c20-0921-4a58-adfc-02ec8f091dc8">98-0443284</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Commission File Number)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(IRS Employer Identification No.)</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ic17d4fc9834d42c89f5760ffacbfc11f_D20230207-20230207" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmQ3NjA1ODlkMTBhMTQyZWM4NTA0MjNmNDZkNGQxMDYwL3NlYzpkNzYwNTg5ZDEwYTE0MmVjODUwNDIzZjQ2ZDRkMTA2MF8xL2ZyYWc6YTRlMzNmNjk2ZTdkNDYwNmE0OTVkYmQzZjA0MWZlZTkvdGV4dHJlZ2lvbjphNGUzM2Y2OTZlN2Q0NjA2YTQ5NWRiZDNmMDQxZmVlOV8xNjQ5MjY3NDQzMTgz_279abdea-0540-45d2-a7e0-626a1250486c">332 Encinitas Blvd.</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ic17d4fc9834d42c89f5760ffacbfc11f_D20230207-20230207" name="dei:EntityAddressAddressLine2" id="id3VybDovL2RvY3MudjEvZG9jOmQ3NjA1ODlkMTBhMTQyZWM4NTA0MjNmNDZkNGQxMDYwL3NlYzpkNzYwNTg5ZDEwYTE0MmVjODUwNDIzZjQ2ZDRkMTA2MF8xL2ZyYWc6YTRlMzNmNjk2ZTdkNDYwNmE0OTVkYmQzZjA0MWZlZTkvdGV4dHJlZ2lvbjphNGUzM2Y2OTZlN2Q0NjA2YTQ5NWRiZDNmMDQxZmVlOV8xMzEy_3417a46d-d7a8-4ebf-98d6-307b0679fa65">Suite 102</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ic17d4fc9834d42c89f5760ffacbfc11f_D20230207-20230207" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmQ3NjA1ODlkMTBhMTQyZWM4NTA0MjNmNDZkNGQxMDYwL3NlYzpkNzYwNTg5ZDEwYTE0MmVjODUwNDIzZjQ2ZDRkMTA2MF8xL2ZyYWc6YTRlMzNmNjk2ZTdkNDYwNmE0OTVkYmQzZjA0MWZlZTkvdGV4dHJlZ2lvbjphNGUzM2Y2OTZlN2Q0NjA2YTQ5NWRiZDNmMDQxZmVlOV8xMzE1_a507bd77-9d09-49ef-92f9-447b9e57253b">Encinitas</ix:nonNumeric>,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ic17d4fc9834d42c89f5760ffacbfc11f_D20230207-20230207" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOmQ3NjA1ODlkMTBhMTQyZWM4NTA0MjNmNDZkNGQxMDYwL3NlYzpkNzYwNTg5ZDEwYTE0MmVjODUwNDIzZjQ2ZDRkMTA2MF8xL2ZyYWc6YTRlMzNmNjk2ZTdkNDYwNmE0OTVkYmQzZjA0MWZlZTkvdGV4dHJlZ2lvbjphNGUzM2Y2OTZlN2Q0NjA2YTQ5NWRiZDNmMDQxZmVlOV8xMzE2_a9a8a383-9cb3-4fe6-ba96-4dd1931f6d81">CA</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ic17d4fc9834d42c89f5760ffacbfc11f_D20230207-20230207" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmQ3NjA1ODlkMTBhMTQyZWM4NTA0MjNmNDZkNGQxMDYwL3NlYzpkNzYwNTg5ZDEwYTE0MmVjODUwNDIzZjQ2ZDRkMTA2MF8xL2ZyYWc6YTRlMzNmNjk2ZTdkNDYwNmE0OTVkYmQzZjA0MWZlZTkvdGV4dHJlZ2lvbjphNGUzM2Y2OTZlN2Q0NjA2YTQ5NWRiZDNmMDQxZmVlOV80MjA_0678b234-d3c2-43e5-a67f-2ed58da96cb8">92024</ix:nonNumeric></span></div><div style="margin-top:8pt;text-align:center"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="ic17d4fc9834d42c89f5760ffacbfc11f_D20230207-20230207" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmQ3NjA1ODlkMTBhMTQyZWM4NTA0MjNmNDZkNGQxMDYwL3NlYzpkNzYwNTg5ZDEwYTE0MmVjODUwNDIzZjQ2ZDRkMTA2MF8xL2ZyYWc6YTRlMzNmNjk2ZTdkNDYwNmE0OTVkYmQzZjA0MWZlZTkvdGV4dHJlZ2lvbjphNGUzM2Y2OTZlN2Q0NjA2YTQ5NWRiZDNmMDQxZmVlOV80MjQ_f797fd94-f74b-4f6e-9974-317274470012">781</ix:nonNumeric>) <ix:nonNumeric contextRef="ic17d4fc9834d42c89f5760ffacbfc11f_D20230207-20230207" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmQ3NjA1ODlkMTBhMTQyZWM4NTA0MjNmNDZkNGQxMDYwL3NlYzpkNzYwNTg5ZDEwYTE0MmVjODUwNDIzZjQ2ZDRkMTA2MF8xL2ZyYWc6YTRlMzNmNjk2ZTdkNDYwNmE0OTVkYmQzZjA0MWZlZTkvdGV4dHJlZ2lvbjphNGUzM2Y2OTZlN2Q0NjA2YTQ5NWRiZDNmMDQxZmVlOV8xMzIw_d4a1cae0-71de-410a-a36d-27b6c9b80ac4">788-9043</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="margin-top:8pt;text-align:center"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Former name or former address, if changed since last report)</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:1.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.870%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic17d4fc9834d42c89f5760ffacbfc11f_D20230207-20230207" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmQ3NjA1ODlkMTBhMTQyZWM4NTA0MjNmNDZkNGQxMDYwL3NlYzpkNzYwNTg5ZDEwYTE0MmVjODUwNDIzZjQ2ZDRkMTA2MF8xL2ZyYWc6YTRlMzNmNjk2ZTdkNDYwNmE0OTVkYmQzZjA0MWZlZTkvdGFibGU6NTFmMjdlNzI4ZDc2NDk5NmJiNGNjMzM4OTY1NGIyNTcvdGFibGVyYW5nZTo1MWYyN2U3MjhkNzY0OTk2YmI0Y2MzMzg5NjU0YjI1N18wLTAtMS0xLTMzOTc_de7ea117-05c0-4891-9a12-9ed7fff949c6">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic17d4fc9834d42c89f5760ffacbfc11f_D20230207-20230207" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmQ3NjA1ODlkMTBhMTQyZWM4NTA0MjNmNDZkNGQxMDYwL3NlYzpkNzYwNTg5ZDEwYTE0MmVjODUwNDIzZjQ2ZDRkMTA2MF8xL2ZyYWc6YTRlMzNmNjk2ZTdkNDYwNmE0OTVkYmQzZjA0MWZlZTkvdGFibGU6NTFmMjdlNzI4ZDc2NDk5NmJiNGNjMzM4OTY1NGIyNTcvdGFibGVyYW5nZTo1MWYyN2U3MjhkNzY0OTk2YmI0Y2MzMzg5NjU0YjI1N18yLTAtMS0xLTMzOTc_11f7d719-c49b-47aa-ba97-f7efee15a6ba">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic17d4fc9834d42c89f5760ffacbfc11f_D20230207-20230207" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmQ3NjA1ODlkMTBhMTQyZWM4NTA0MjNmNDZkNGQxMDYwL3NlYzpkNzYwNTg5ZDEwYTE0MmVjODUwNDIzZjQ2ZDRkMTA2MF8xL2ZyYWc6YTRlMzNmNjk2ZTdkNDYwNmE0OTVkYmQzZjA0MWZlZTkvdGFibGU6NTFmMjdlNzI4ZDc2NDk5NmJiNGNjMzM4OTY1NGIyNTcvdGFibGVyYW5nZTo1MWYyN2U3MjhkNzY0OTk2YmI0Y2MzMzg5NjU0YjI1N180LTAtMS0xLTMzOTc_79fe3507-aaf6-4780-ba64-28504cf3f3dd">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic17d4fc9834d42c89f5760ffacbfc11f_D20230207-20230207" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmQ3NjA1ODlkMTBhMTQyZWM4NTA0MjNmNDZkNGQxMDYwL3NlYzpkNzYwNTg5ZDEwYTE0MmVjODUwNDIzZjQ2ZDRkMTA2MF8xL2ZyYWc6YTRlMzNmNjk2ZTdkNDYwNmE0OTVkYmQzZjA0MWZlZTkvdGFibGU6NTFmMjdlNzI4ZDc2NDk5NmJiNGNjMzM4OTY1NGIyNTcvdGFibGVyYW5nZTo1MWYyN2U3MjhkNzY0OTk2YmI0Y2MzMzg5NjU0YjI1N182LTAtMS0xLTMzOTc_979690c5-dac1-480a-831a-48b3b1c16115">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr></table></div><div style="margin-top:8pt;text-align:justify"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.203%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.204%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Title of each class:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name of each exchange on which registered:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic17d4fc9834d42c89f5760ffacbfc11f_D20230207-20230207" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmQ3NjA1ODlkMTBhMTQyZWM4NTA0MjNmNDZkNGQxMDYwL3NlYzpkNzYwNTg5ZDEwYTE0MmVjODUwNDIzZjQ2ZDRkMTA2MF8xL2ZyYWc6YTRlMzNmNjk2ZTdkNDYwNmE0OTVkYmQzZjA0MWZlZTkvdGFibGU6NDBmN2IyYjk2NWNmNDgzZjkwNzI2MjM2MjU3MjRjNzcvdGFibGVyYW5nZTo0MGY3YjJiOTY1Y2Y0ODNmOTA3MjYyMzYyNTcyNGM3N18xLTAtMS0xLTMzOTc_ed9adefd-e08c-4b72-9363-0d3162df13d6">Common Stock, $0.01 par value</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic17d4fc9834d42c89f5760ffacbfc11f_D20230207-20230207" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmQ3NjA1ODlkMTBhMTQyZWM4NTA0MjNmNDZkNGQxMDYwL3NlYzpkNzYwNTg5ZDEwYTE0MmVjODUwNDIzZjQ2ZDRkMTA2MF8xL2ZyYWc6YTRlMzNmNjk2ZTdkNDYwNmE0OTVkYmQzZjA0MWZlZTkvdGFibGU6NDBmN2IyYjk2NWNmNDgzZjkwNzI2MjM2MjU3MjRjNzcvdGFibGVyYW5nZTo0MGY3YjJiOTY1Y2Y0ODNmOTA3MjYyMzYyNTcyNGM3N18xLTItMS0xLTMzOTc_7b29d764-7d4b-4103-a27b-678bcffa6689">KPRX</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic17d4fc9834d42c89f5760ffacbfc11f_D20230207-20230207" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOmQ3NjA1ODlkMTBhMTQyZWM4NTA0MjNmNDZkNGQxMDYwL3NlYzpkNzYwNTg5ZDEwYTE0MmVjODUwNDIzZjQ2ZDRkMTA2MF8xL2ZyYWc6YTRlMzNmNjk2ZTdkNDYwNmE0OTVkYmQzZjA0MWZlZTkvdGFibGU6NDBmN2IyYjk2NWNmNDgzZjkwNzI2MjM2MjU3MjRjNzcvdGFibGVyYW5nZTo0MGY3YjJiOTY1Y2Y0ODNmOTA3MjYyMzYyNTcyNGM3N18xLTQtMS0xLTMzOTc_f22e9c6e-d722-4cb1-bd5c-4ab176ee1532">NASDAQ</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:8pt;text-align:justify"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule&#160;12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ic17d4fc9834d42c89f5760ffacbfc11f_D20230207-20230207" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmQ3NjA1ODlkMTBhMTQyZWM4NTA0MjNmNDZkNGQxMDYwL3NlYzpkNzYwNTg5ZDEwYTE0MmVjODUwNDIzZjQ2ZDRkMTA2MF8xL2ZyYWc6YTRlMzNmNjk2ZTdkNDYwNmE0OTVkYmQzZjA0MWZlZTkvdGV4dHJlZ2lvbjphNGUzM2Y2OTZlN2Q0NjA2YTQ5NWRiZDNmMDQxZmVlOV8xMzEx_ebb2121f-2cdf-4df9-ab8b-1e38872c481b">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#212529;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="id760589d10a142ec850423f46d4d1060_7"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 8.01.&#160;&#160;&#160;&#160;Other Events.</span></div><div style="margin-top:10pt"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 7, 2023, Kiora Pharmaceuticals, Inc. (the &#8220;Company&#8221;) issued a press release announcing that it has received investigational new drug application approval for a Phase 2 study of KIO-101 for the treatment of the Ocular Presentation of Rheumatoid Arthritis or other autoimmune diseases (OPRA+). A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.</span></div><div style="text-align:justify"><span><br/></span></div><div id="id760589d10a142ec850423f46d4d1060_10"></div><div style="-sec-extract:summary;margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9.01.&#160;&#160;&#160;&#160;Financial Statements and Exhibits.</span></div><div style="margin-top:10pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(d)</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:1.28pt">Exhibits.</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exhibit&#160;<br/>Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title</span></td></tr><tr style="height:11pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="ex991-pressreleasekiox101p.htm">99.1</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex991-pressreleasekiox101p.htm">Press Release of Kiora Pharmaceuticals, Inc., dated as of February 7, 2023.</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (embedded within the Inline XBRL document).</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="id760589d10a142ec850423f46d4d1060_13"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:10pt;text-align:center"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.869%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.841%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">KIORA PHARMACEUTICALS, INC.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Brian M. Strem, Ph.D.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brian M. Strem, Ph.D.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: February 7, 2023</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
[{"type": "8-K", "sequence": "1", "filename": "kprx-20230207.htm", "description": "8-K", "secsgml_size_bytes": 33850}]
{"company-data": {"conformed-name": "KIORA PHARMACEUTICALS INC", "cik": "0001372514", "assigned-sic": "2834", "irs-number": "000000000", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "001-36672", "film-number": "23592746"}, "business-address": {"street1": "332 ENCINITAS BOULEVARD", "street2": "SUITE 102", "city": "ENCINITAS", "state": "CA", "zip": "92024", "phone": "781-788-8869"}, "mail-address": {"street1": "332 ENCINITAS BOULEVARD", "street2": "SUITE 102", "city": "ENCINITAS", "state": "CA", "zip": "92024"}, "former-company": {"former-conformed-name": "EYEGATE PHARMACEUTICALS INC", "date-changed": "20060811"}}
kprx-20230207
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM
8-K
CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported):
February 7, 2023
KIORA PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
Delaware
(State or other jurisdiction of incorporation)
001-36672
98-0443284
(Commission File Number)
(IRS Employer Identification No.)
332 Encinitas Blvd.
Suite 102
Encinitas
,
CA
92024
(
781
)
788-9043
(Registrant's telephone number, including area code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class:
Trading Symbol(s)
Name of each exchange on which registered:
Common Stock, $0.01 par value
KPRX
NASDAQ
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
o
Item 8.01.    Other Events.
On February 7, 2023, Kiora Pharmaceuticals, Inc. (the "Company") issued a press release announcing that it has received investigational new drug application approval for a Phase 2 study of KIO-101 for the treatment of the Ocular Presentation of Rheumatoid Arthritis or other autoimmune diseases (OPRA+). A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Item 9.01.    Financial Statements and Exhibits.
(d)
Exhibits.
Exhibit
Number
Title
99.1
Press Release of Kiora Pharmaceuticals, Inc., dated as of February 7, 2023.
104
Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
KIORA PHARMACEUTICALS, INC.
By:
/s/ Brian M. Strem, Ph.D.
Brian M. Strem, Ph.D.
President and Chief Executive Officer
Date: February 7, 2023